Laà la-AÃ cha Hanafi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10942849/publications.pdf

Version: 2024-02-01

15 papers	5,535 citations	13 h-index	996975 15 g-index
15	15	15	6786
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. Journal of Clinical Investigation, 2016, 126, 2123-2138.	8.2	1,657
2	Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discovery, 2017, 7, 1404-1419.	9.4	945
3	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells. Science Translational Medicine, 2016, 8, 355ra116.	12.4	832
4	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood, 2017, 130, 2295-2306.	1.4	774
5	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib. Journal of Clinical Oncology, 2017, 35, 3010-3020.	1.6	568
6	Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives. Clinical Cancer Research, 2011, 17, 6985-6991.	7.0	343
7	Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nature Communications, 2020, 11, 219.	12.8	167
8	A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells. Proteomics, 2013, 13, 1108-1120.	2.2	91
9	Human Activated T Lymphocytes Modulate IDO Expression in Tumors through Th1/Th2 Balance. Journal of Immunology, 2009, 183, 7752-7760.	0.8	47
10	IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive. Molecular Immunology, 2011, 49, 253-259.	2.2	31
11	Fludarabine Downregulates Indoleamine 2,3-Dioxygenase in Tumors via a Proteasome-Mediated Degradation Mechanism. PLoS ONE, 2014, 9, e99211.	2.5	23
12	Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. Vaccine, 2010, 28, 5617-5626.	3.8	21
13	Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells Journal of Clinical Oncology, 2016, 34, 102-102.	1.6	20
14	CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 56-56.	1.4	11
15	MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy. PLoS ONE, 2021, 16, e0261987.	2.5	5